CTNNB1 and hepatocellular carcinoma: An integrated analysis of the molecular features showed that the 6 responders to pembrolizumab in our study were characterized by lower levels of immunosuppressive tumor endogenous or microenvironment elements (CTNNB1 mutations, neutrophils, ECM, and stroma signatures), and increased levels of T-cell cytotoxicity and cell proliferation, delineating a particular class of HCC that is most likely to benefit from pembrolizumab.